Research
Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces significant weight loss (up to -9.5 kg with 15 mg dose) in patients with type 2 diabetes over 40 weeks.
Tirzepatide is a dual-acting injection that helps you lose up to 9.5 kg over 40 weeks. It works by mimicking hormones that regulate blood sugar and appetite. It is used for people with type 2 diabetes who need better control. Side effects like nausea are common but often temporary.
StrongSupportsHIGH confidence
Ao final das 40 semanas, o peso corporal diminuiu significativamente sendo a perda de peso de –7,0 kg no grupo com dose 5 mg, –7,8 kg no grupo 10 mg, –9,5 kg (0∙54) no grupo 15 mg e –0,7 kg no grupo placebo (Rosenstock et al., 2021).
Why this rating
Based on a double-blind, placebo-controlled randomized clinical trial.
Source
TERAPIAS FARMACOLÓGICAS PARA TRATAR OBESIDADE: ANÁLISE DE EFEITO E EFICÁCIA
Túlio Martins Freitas et al. · Revista Foco · 2024
narrative_reviewCited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →